Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with hodgkin's disease

Melissa M. Hudson, Carol Greenwald, Elizabeth Thompson, Judith Wilimas, Neyssa Marina, Diane Fairclough, William Kauffman, Paula Bozeman, Paul W. Mackert, Minnie Abromowitch, Jesse Jenkins, Thomas Boulden, Larry Kun

Research output: Contribution to journalArticle

125 Scopus citations

Abstract

Purpose: Between May 1980 and September 1990, 85 patients with Hodgkin's disease were treated with a regimen designed to increase cure rates while reducing late toxicity. Patients and Methods: Therapy consisted of five cycles of cyclophosphamide, Oncovin (vincristine; Eli Lilly and Co, Indianapolis, IN), and procarbazine (COP), alternated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and low-dose (20 Gy) regional radiotherapy. Vincristine and cyclophosphamide were administered as tolerated during irradiation and during the 2- to 4-week rest period between radiation volumes. The need for staging laparotomy was defined by clinical presentation. Results: The median age at diagnosis was 14 years (range, 4 to 20), and 56% of patients were male. The majority (67%) had stage III or IV disease and 68% (19 of 28) of stage II patients had bulky mediastinal disease. Nodular sclerosing histology predominated (67%). Ninety-three percent of patients were alive without disease with a median follow-up of 4.1 years. Abnormalities were detected on chest roentgenograms and/or pulmonary function tests in 58% and 25% of clinically asymptomatic patients who were tested at least 1 year after completion of therapy. The only symptomatic patient had pulmonary fibrosis after treatment with bleomycin (20 U/m2) and mantle (20 Gy)/lung (13 Gy) irradiation, and developed multiple spontaneous pneumothoraces that required cortical stripping. One patient had congestive heart failure 19 months post-treatment, and two had abnormalities on echocardiograms. Thyroid abnormalities occurred in 21 (27%) patients who were assessable for late toxicity. The majority of female patients have had regular menstrual cycles. Six developed ovarian failure, and 10 have had a total of 17 pregnancies. Other than one documented case of oligospermia, information was not available on male fertility. Conclusion: The results demonstrate excellent disease control for the COP/ABVD regimen, with acceptable toxicity.

Original languageEnglish (US)
Pages (from-to)100-108
Number of pages9
JournalJournal of Clinical Oncology
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 1 1993

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this